# Phase 1 Study of Drug-Drug Interactions Between DWP16001, DWC202407, and DWC202408 in Healthy Adults

> **NCT06644404** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 34 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** DWP16001 0.3mg
- **DRUG:** DWC202407 1,000mg
- **DRUG:** DWC202408 2mg

## Key facts

- **NCT ID:** NCT06644404
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-10-26
- **Primary completion:** 2024-12-03
- **Final completion:** 2025-04-01
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2024-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06644404

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06644404, "Phase 1 Study of Drug-Drug Interactions Between DWP16001, DWC202407, and DWC202408 in Healthy Adults". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06644404. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*